Docetaxel–Chitosan nanoparticles for breast cancer treatment: cell viability and gene expression study

• DOI: 10.1111/cbdd.12814
• Publication Date: 2016-07-07T15:06:45Z
• Authors: Zahra H. Mirzaie; Shiva Irani; Reza Mirfakhraie; Seyed Mohammad At...; Meshkat Dinarvand; Rassoul Dinarvand; Reyhaneh Varshochian; Fatemeh Atyabi
• Keywords: Viability assay; Zeta potential

Docetaxel acts through the inhibition of tubulin polymerization and reduction in expression BCL-2 gene. In this study, nanoparticles containing were prepared their effects on gene levels BAX genes investigated. The drug was first conjugated to chitosan, assembled presence hyaluronic acid. Conjugations confirmed by 1 H-NMR, obtained characterized dynamic light scattering SEM. Cytotoxicity nanoparticles, cellular uptake, cell death evaluated. Finally, effect MCF-7 cells investigated real-time PCR. results revealed that NPs had spherical shape with narrow size distribution <200 nm positive zeta potentials. vitro cytotoxicity Cs free investigations increasing treatment time led decrease rate viability. expressions decreased nanoparticle-treated comparison intact cells, while BAX/BCL-2 ratio significantly elevated compared drug-treated after 72 h. Docetaxel-conjugated may offer a promising low off-target toxicity for breast cancer.